CMPF

TargetMol
Product Code: TAR-T68490
Supplier: TargetMol
CodeSizePrice
TAR-T68490-1mg1mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68490-5mg5mg£388.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68490-10mg10mg£543.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68490-25mg25mg£825.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68490-50mg50mg£1,099.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68490-100mg100mg£1,452.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
CMPF is a microtubule protein inhibitor that can be used to study tumors.
CAS:
86879-39-2
Formula:
C12H16O5
Molecular Weight:
240.25
Pathway:
Cytoskeletal Signaling
Purity:
0.995
SMILES:
O=C(O)C1=C(OC(=C1C)CCC)CCC(=O)O
Target:
Microtubule Associated

References

Lim CF, et al. A naturally occurring furan fatty acid enhances drug inhibition of thyroxine binding in serum. Metabolism. 1993;42(11):1468-1474. Lim CF, et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab. 1993;76(2):318-324. Liu G, et al. Pure omega 3 polyunsaturated fatty acids (EPA, DPA or DHA) are associated with increased plasma levels of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) in a short-term study in women. Food Funct. 2020;11(3):2058-2066. Lankinen MA, et al. CMPF does not associate with impaired glucose metabolism in individuals with features of metabolic syndrome. PLoS One. 2015;10(4):e0124379. Miao Z, et al. Furan fatty acid metabolite CMPF is associated with lower risk of type 2 diabetes, but not chronic kidney disease: a longitudinal population-based cohort study. Am J Clin Nutr. 2023;S0002-9165(23)66060-5. Dai L, et al. The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study. Am J Clin Nutr. 2022;116(6):1842-1851.